J.P. Morgan Maintains a Buy Rating on CeriBell (CBLL) With a $21 PT

CeriBell, Inc. (NASDAQ:CBLL) is one of the best medical device stocks to buy according to analystsJ.P. Morgan analyst Robbie Marcus maintained a Buy rating on CeriBell, Inc. (NASDAQ:CBLL) on August 5, setting a price target of $21.00.

5 Fastest Growing Health Tech Companies in the World

A medical technician in a lab coat overseeing a complex piece of healthcare technology equipment.

The rating update came after CeriBell, Inc. (NASDAQ:CBLL) reported its Q2 results on the same day, with total revenue for the quarter reaching $21.2 million and reflecting a 38% growth compared to the same quarter last year.

CeriBell, Inc. (NASDAQ:CBLL) also attained a gross margin of 88% in Q2 2025, and ended the quarter with 584 total active accounts.

CeriBell, Inc. (NASDAQ:CBLL) is a commercial-stage medical technology company that engages in the diagnosis and management of patients with serious neurological conditions. The company’s products include Point-of-Care EEG, EEG Portal, and Clarity.

While we acknowledge the potential of CBLL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CBLL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.